Chemistry:Zanzalintinib
From HandWiki
Short description: Drug currently undergoing clinical studies
 | |
| Clinical data | |
|---|---|
| Other names | XL092 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C29H25FN4O5 |
| Molar mass | 528.540 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Zanzalintinib (also known as XL092) is an oral drug that is undergoing clinical studies. It could potentially be used to treat renal cell carcinoma (RCC). It is being developed by Exelixis.[1][2]
STELLAR-303 is a phase 3, randomized study of zanzalintinib in combination with atezolizumab versus regorafenib in metastatic colorectal cancer.[3]
STELLAR-304 (NCT05678673) is a phase 3, randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC).[4]
References
- ↑ "481P A phase I first-in-human study of XL092 in patients (pts) with locally advanced or metastatic solid tumors: Results from dose-escalation of XL092 alone and in combination with atezolizumab". Annals of Oncology 33: S760. September 2022. doi:10.1016/j.annonc.2022.07.609. ISSN 0923-7534.
- ↑ "Stellar 002" (in en). STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. https://www.stellarclinicaltrials.com/stellar-002.
- ↑ "Stellar 303" (in en). STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. https://www.stellarclinicaltrials.com/stellar-303.
- ↑ "Stellar 304" (in en). STELLAR Clinical Trials Program (Exelixis). Official US HCP Website. https://www.stellarclinicaltrials.com/stellar-304.
 |  |
